Cargando…
Barriers to antibody therapy in solid tumors, and their solutions
Antibody drugs have become the mainstream of cancer treatment due to advances in cancer biology and Ab engineering. However, several barriers to Ab therapy have also been identified. These include various mechanisms for Ab drug resistance, such as heterogeneity of antigen expression in tumor cells a...
Autor principal: | Matsumura, Yasuhiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353947/ https://www.ncbi.nlm.nih.gov/pubmed/34032331 http://dx.doi.org/10.1111/cas.14983 |
Ejemplares similares
-
Barriers to drug delivery in solid tumors
por: Sriraman, Shravan Kumar, et al.
Publicado: (2014) -
Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors
por: Middelburg, Jim, et al.
Publicado: (2021) -
Recent advances of bispecific antibodies in solid tumors
por: Yu, Shengnan, et al.
Publicado: (2017) -
Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors
por: Alcantara, Marion, et al.
Publicado: (2020) -
Recent advances and challenges of bispecific antibodies in solid tumors
por: Wu, Yuze, et al.
Publicado: (2021)